DUBLIN and BUDAPEST, Hungary, April 3, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Gedeon Richter Plc., today announced positive topline results for RGH-MD-53, a Phase 3 study of cariprazine for the treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar I depression). The companies announced in December 2017 positive topline results for the second pivotal trial (RGH-MD-54) of cariprazine in the treatment of bipolar I depression. In that trial both cariprazine 1.5mg and 3mg were statistically greater than placebo.

DUBLIN, April 2, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced it has received the 2018 ENERGY STAR^® Partner of the Year Sustained Excellence Award. The Company is being recognized by the U.S. Environmental Protection Agency for its leadership in energy management and efficiency.

DUBLIN, April 2, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it intends to release first quarter 2018 financial results on Monday, April 30, 2018, prior to the open of U.S. financial markets. Allergan will host a conference call and webcast at 8:30 a.m. Eastern Time on Monday, April 30, 2018 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the conference ID is 67781149.

NEW YORK, March 6, 2018 /PRNewswire/ -- CoolSculpting^® teamed up with figure skating superstar and sports correspondent Johnny Weir to share his tips for looking his best at the CoolSculpting^® on Ice event at The Rink at Rockefeller Center in New York City on Monday, March 5, 2018. Weir hosted an ice skating master class to discuss his life-long commitment to a healthy lifestyle, including his experience with the CoolSculpting^® treatment CoolSculpting^® is an FDA-cleared non-surgical, clinically proven treatment that eliminates stubborn fat using a patented cooling technology, owned by Allergan plc (NYSE: AGN).

DUBLIN, Feb. 28, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, today announced that it was notified by the U.S. Food and Drug Administration (FDA) that the review of the New Drug Application (NDA) for ulipristal acetate will be extended. The PDUFA target action date has been extended to August 2018 to provide time for a full review of the file.

DUBLIN, Feb. 28, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the Barclays Global Healthcare Conference in Miami, FL. The presentation will begin at 1:35 p.m. Eastern Time on Wednesday, March 14, 2018.

DUBLIN, Feb. 26, 2018 /PRNewswire/ -- Allergan plc (NYSE:AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Cowen and Company 38^th Annual Health Care Conference in Boston, Massachusetts. The presentation will begin at 3:30 p.m. Eastern Time on Monday, March 12, 2018.

DUBLIN and SAN FRANCISCO, Feb. 22, 2018 /PRNewswire/ -- Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Medicines360's supplemental New Drug Application (sNDA). The application aims to extend the duration of use for the prevention of pregnancy from up to four years to up to five years for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg. 

DUBLIN, Feb. 16, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, February 16-20, 2018. The meeting will be held at the San Diego Convention Center and the scheduled times (noted in local Pacific Time) for the Allergan presentations, titles and authors are as follows:

DUBLIN, Feb. 9, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced its Board of Directors has declared a cash dividend of $0.72 per ordinary share for the first quarter of 2018. The dividend will be paid on March 28, 2018 to shareholders of record at the close of business on February 28, 2018.